Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | A. Zeidan, P. Becker, P. Patel, G. Schiller, M.L. Tsai, T. Lin, E. Wang, M. Erlander,J. Cortes | ||||||||||||
Title | Polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed/refractory acute myeloid leukaemia in phase Ib | ||||||||||||
|
|||||||||||||
URL | https://www.annalsofoncology.org/article/S0923-7534(19)59279-1/fulltext | ||||||||||||
Abstract Text | Annals of Oncology30 (Supplement 5): v435–v448, 2019, doi:10.1093/annonc/mdz251 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|